Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials

Hepatology Research

Volumn 42, Issue 8, 2012, Pages 782-789

  Qu, Li Shuai ^a   Chen, Hong ^a   Kuai, Xiao Ling ^a   Xu, Zheng Fu ^a   Jin, Fei ^b   Zhou, Guo Xiong ^a  

^a NANTONG UNIVERSITY   (China)

^b SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INTERFERON; PEGINTERFERON;

ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; DRUG RESPONSE; DRUG TREATMENT FAILURE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84863736820     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00984.x     Document Type: Article

References (32)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
3. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the hepatitis C virus. Science 2001; 292: 2323-5.
4. Tsukuma H, Hiyama T, Tanaka S etal. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
5. Poynard T, Opolon P. Hepatitis C: somber views of natural history and optimistic views of interferon treatment? Hepatology 1998; 27: 1443-4.
6. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994; 20: 1225-30.
7. von Marschall Z, Scholz A, Cramer T etal. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-48.
8. Wang L, Wu WZ, Sun HC etal. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003; 7: 587-94.
9. Nishiguchi S, Kuroki T, Nakatani S etal. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
10. Nishiguchi S, Shiomi S, Nakatani S etal. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196-7.
11. Valla DC, Chevallier M, Marcellin P etal. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
12. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689-98.
13. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
14. Singal AK, Singh A, Jaganmohan S etal. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-9.
15. Bernardinello E, Cavalletto L, Chemello L etal. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999; 46: 3216-22.
16. Planas R, Quer JC, Enriquez J etal. Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study. Med Clin (Barc) 2002; 118: 641-4.
17. Azzaroli F, Accogli E, Nigro G etal. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004; 10: 3099-102.
18. Fartoux L, Degos F, Trepo C etal. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007; 5: 502-7.
19. Lok AS, Everhart JE, Wright EC etal. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-9.
20. Bruix J, Poynard T, Colombo M etal. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011; 140: 1990-9.
21. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26: 128S-32S.
22. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 2011; 16: 787-95.
23. Fink SA, Jacobson IM. Managing patients with hepatitisB-related or hepatitisC-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2011; 8: 285-95.
24. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233-40.
25. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
26. Veldt BJ, Heathcote EJ, Wedemeyer H etal. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
27. Mallet V, Gilgenkrantz H, Serpaggi J etal. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
28. Di Bisceglie AM, Shiffman ML, Everson GT etal. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
29. Nakaji M, Yano Y, Ninomiya T etal. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389-97.
30. Baron S, Tyring SK, Fleischmann WR etal. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-83.
31. Cheng SJ, Freeman RB Jr, Wong JB. Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma. Liver Transpl 2002; 8: 323-8.
32. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351: 1535-9.